BioXcel Therapeutics Appoints Vincent O’Neill Chief Medical Officer

Vincent O’Neill has been appointed senior vice president and chief medical officer of BioXcel Therapeutics (NASDAQ: [[ticker:BTAI]]). O’Neill had been serving as chief medical officer of the Branford, CT, company on a consulting basis since last July. His experience also includes senior roles at Genentech, Sanofi (NYSE: [[ticker:SNY]]), GlaxoSmithKline (NYSE: [[ticker:GSK]]), and Mirna Therapeutics. Earlier this year, BioXcel completed an IPO to finance clinical testing on a pair of drugs it found with the help of its artificial intelligence technology.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan